178 related articles for article (PubMed ID: 20368203)
1. HOMA-beta in the UKPDS and ADOPT. Is the natural history of type 2 diabetes characterised by a progressive and inexorable loss of insulin secretory function? Maybe? Maybe not?
Reaven GM
Diab Vasc Dis Res; 2009 Apr; 6(2):133-8. PubMed ID: 20368203
[No Abstract] [Full Text] [Related]
2. Vildagliptin added to metformin on β-cell function after a euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetes patients.
Derosa G; Ragonesi PD; Carbone A; Fogari E; Bianchi L; Bonaventura A; Romano D; Cicero AF; Maffioli P
Diabetes Technol Ther; 2012 Jun; 14(6):475-84. PubMed ID: 22512264
[TBL] [Abstract][Full Text] [Related]
3. A model for glucose, insulin, and beta-cell dynamics in subjects with insulin resistance and patients with type 2 diabetes.
Ribbing J; Hamrén B; Svensson MK; Karlsson MO
J Clin Pharmacol; 2010 Aug; 50(8):861-72. PubMed ID: 20484615
[TBL] [Abstract][Full Text] [Related]
4. Pancreatic β cells: Gatekeepers of type 2 diabetes.
Park YJ; Woo M
J Cell Biol; 2019 Apr; 218(4):1094-1095. PubMed ID: 30696700
[TBL] [Abstract][Full Text] [Related]
5. Goals of treatment for type 2 diabetes: beta-cell preservation for glycemic control.
Marchetti P; Lupi R; Del Guerra S; Bugliani M; D'Aleo V; Occhipinti M; Boggi U; Marselli L; Masini M
Diabetes Care; 2009 Nov; 32 Suppl 2(Suppl 2):S178-83. PubMed ID: 19875548
[No Abstract] [Full Text] [Related]
6. Association of hematological parameters with insulin resistance and beta-cell dysfunction in nondiabetic subjects.
Hanley AJ; Retnakaran R; Qi Y; Gerstein HC; Perkins B; Raboud J; Harris SB; Zinman B
J Clin Endocrinol Metab; 2009 Oct; 94(10):3824-32. PubMed ID: 19622625
[TBL] [Abstract][Full Text] [Related]
7. Tenacious D. why beta cells are no match for the relentless persistence of type 2 diabetes.
Curry A
Diabetes Forecast; 2015; 68(5):38-41. PubMed ID: 26491753
[No Abstract] [Full Text] [Related]
8. Serum bilirubin concentrations are positively associated with serum C-peptide levels in patients with Type 2 diabetes.
Chung JO; Cho DH; Chung DJ; Chung MY
Diabet Med; 2014 Nov; 31(11):1316-22. PubMed ID: 24910105
[TBL] [Abstract][Full Text] [Related]
9. Anti-Diabetic Activities of Gastrodia elata Blume Water Extracts Are Mediated Mainly by Potentiating Glucose-Stimulated Insulin Secretion and Increasing β-Cell Mass in Non-Obese Type 2 Diabetic Animals.
Yang HJ; Kim MJ; Kwon DY; Kim DS; Lee YH; Kim JE; Park S
Nutrients; 2016 Mar; 8(3):161. PubMed ID: 26978400
[TBL] [Abstract][Full Text] [Related]
10. The importance of rapid insulin secretion: revisited.
Grodsky GM
Diabetes Technol Ther; 1999; 1(3):259-60. PubMed ID: 11475271
[No Abstract] [Full Text] [Related]
11. Appropriate therapy for type 2 diabetes mellitus in view of pancreatic β-cell glucose toxicity: "the earlier, the better".
Kaneto H; Matsuoka TA; Kimura T; Obata A; Shimoda M; Kamei S; Mune T; Kaku K
J Diabetes; 2016 Mar; 8(2):183-9. PubMed ID: 26223490
[TBL] [Abstract][Full Text] [Related]
12. A novel Gymnema sylvestre extract stimulates insulin secretion from human islets in vivo and in vitro.
Al-Romaiyan A; Liu B; Asare-Anane H; Maity CR; Chatterjee SK; Koley N; Biswas T; Chatterji AK; Huang GC; Amiel SA; Persaud SJ; Jones PM
Phytother Res; 2010 Sep; 24(9):1370-6. PubMed ID: 20812281
[TBL] [Abstract][Full Text] [Related]
13. The interleukin-1 receptor antagonist anakinra improves first-phase insulin secretion and insulinogenic index in subjects with impaired glucose tolerance.
van Poppel PC; van Asseldonk EJ; Holst JJ; Vilsbøll T; Netea MG; Tack CJ
Diabetes Obes Metab; 2014 Dec; 16(12):1269-73. PubMed ID: 25039318
[TBL] [Abstract][Full Text] [Related]
14. Short-term intensive insulin therapy at diagnosis in type 2 diabetes: plan for filling the gaps.
Weng J; Retnakaran R; Ariachery C A; Ji L; Meneghini L; Yang W; Woo JT
Diabetes Metab Res Rev; 2015 Sep; 31(6):537-44. PubMed ID: 25196375
[TBL] [Abstract][Full Text] [Related]
15. Fate of the beta-cell in the pathophysiology of type 2 diabetes.
Campbell RK
J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S10-5. PubMed ID: 19801360
[TBL] [Abstract][Full Text] [Related]
16. [Pancreatic pacemaker out of rhythm. Disturbed pulsatile insulin release therapeutically interesting in type 2 diabetes].
Sjöholm A
Lakartidningen; 2007 Aug 8-21; 104(32-33):2228-9. PubMed ID: 17822199
[No Abstract] [Full Text] [Related]
17. Defining and characterizing the progression of type 2 diabetes.
Fonseca VA
Diabetes Care; 2009 Nov; 32 Suppl 2(Suppl 2):S151-6. PubMed ID: 19875543
[No Abstract] [Full Text] [Related]
18. Insulin secretory function in type 2 diabetes: Does it matter how you measure it?
Reaven GM
J Diabetes; 2009 Sep; 1(3):142-50. PubMed ID: 20923533
[TBL] [Abstract][Full Text] [Related]
19. Protection of pancreatic beta-cells: is it feasible?
Bonora E
Nutr Metab Cardiovasc Dis; 2008 Jan; 18(1):74-83. PubMed ID: 18096375
[TBL] [Abstract][Full Text] [Related]
20. Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on beta-cell function in normal living conditions.
Mari A; Degn K; Brock B; Rungby J; Ferrannini E; Schmitz O
Diabetes Care; 2007 Aug; 30(8):2032-3. PubMed ID: 17468345
[No Abstract] [Full Text] [Related]
[Next] [New Search]
